Ligand Pharmaceuticals (LGND) Expected to Announce Earnings on Thursday

Ligand Pharmaceuticals (NASDAQ:LGND) is expected to announce its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $1.46 per share and revenue of $55.5890 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Ligand Pharmaceuticals Trading Down 0.2%

NASDAQ:LGND opened at $183.65 on Tuesday. The company has a debt-to-equity ratio of 0.47, a current ratio of 24.69 and a quick ratio of 24.30. The stock has a market capitalization of $3.61 billion, a PE ratio of 88.72 and a beta of 1.14. The business’s 50-day simple moving average is $193.68 and its 200-day simple moving average is $184.61. Ligand Pharmaceuticals has a fifty-two week low of $93.58 and a fifty-two week high of $212.49.

Insiders Place Their Bets

In other Ligand Pharmaceuticals news, Director John W. Kozarich sold 467 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $195.91, for a total value of $91,489.97. Following the completion of the transaction, the director owned 43,187 shares of the company’s stock, valued at $8,460,765.17. This represents a 1.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Octavio Espinoza sold 1,804 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $188.31, for a total value of $339,711.24. Following the completion of the transaction, the chief financial officer directly owned 26,186 shares of the company’s stock, valued at $4,931,085.66. This represents a 6.45% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,205 shares of company stock worth $611,192 in the last 90 days. 7.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Maryland State Retirement & Pension System lifted its holdings in Ligand Pharmaceuticals by 2.2% in the fourth quarter. Maryland State Retirement & Pension System now owns 2,872 shares of the biotechnology company’s stock valued at $543,000 after buying an additional 61 shares during the period. CIBC Private Wealth Group LLC grew its holdings in Ligand Pharmaceuticals by 86.3% in the third quarter. CIBC Private Wealth Group LLC now owns 149 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 69 shares during the period. Cerity Partners LLC increased its stake in Ligand Pharmaceuticals by 5.4% in the fourth quarter. Cerity Partners LLC now owns 1,531 shares of the biotechnology company’s stock valued at $289,000 after purchasing an additional 79 shares in the last quarter. Blair William & Co. IL raised its holdings in shares of Ligand Pharmaceuticals by 1.0% during the fourth quarter. Blair William & Co. IL now owns 8,474 shares of the biotechnology company’s stock valued at $1,602,000 after purchasing an additional 88 shares during the period. Finally, Wellington Management Group LLP boosted its position in shares of Ligand Pharmaceuticals by 1.3% during the 4th quarter. Wellington Management Group LLP now owns 8,426 shares of the biotechnology company’s stock worth $1,593,000 after purchasing an additional 110 shares in the last quarter. Institutional investors own 91.28% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Citigroup started coverage on shares of Ligand Pharmaceuticals in a research report on Tuesday, December 9th. They set a “buy” rating and a $270.00 price objective for the company. Stifel Nicolaus upped their price objective on Ligand Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research note on Wednesday, December 10th. HC Wainwright raised their target price on shares of Ligand Pharmaceuticals from $206.00 to $231.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Ligand Pharmaceuticals in a research report on Monday, December 29th. Finally, Royal Bank Of Canada boosted their price objective on Ligand Pharmaceuticals from $234.00 to $235.00 and gave the stock an “outperform” rating in a report on Wednesday, December 10th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Ligand Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $239.33.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.

The company’s product offerings center around several core platforms.